Literatur
- 1
Alizadeh A A, Eisen M B, Davis R E. et al .
Distinct types of diffuse large B-cell lymphoma identified by gene expression
profiling.
Nature.
2000;
403
503-511
- 2
Anderson J R, Armitage J O, Weisenburger D D.
Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes
differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project.
Ann Oncol.
1998;
9
717-720
- 3
Armitage J O, Weisenburger D D.
New approach to classifying non-Hodgkin’s lymphomas: clinical features of the
major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project.
J Clin Oncol.
1998;
16
2780-2795
- 4
Canellos G P, Skarin A T, Klatt M M. et al .
The m-BACOD combination chemotherapy regimen in the treatment of diffuse large
cell lymphoma.
Semin Hematol.
1987;
24
2-7
- 5
Coiffier B, Ferme F, Hermine O. et al .
Rituximab plus CHOP (CHOP-R) in the treatment of elderly patients with diffuse
large B-cell lymphoma. An update of the GELA study (abstract).
Blood.
2001;
97
405
- 6
Coiffier B, Lepage E, Briere J. et al .
CHOP chemotherapy plus rituximab compared with CHOP Alone in elderly patients
with diffuse large-B-cell lymphoma.
N Engl J Med.
2002;
346
235-242
- 7
Fisher R I, Gaynor E R, Dahlberg S. et al .
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens
for advanced non-Hodgkin’s lymphoma.
New Engl Journ Med.
1993;
328
1002-1006
- 8
Fisher R I, Longo D L, DeVita V T. et al .
Long-term follow up of ProMACE-CytaBOM in non-Hodgkin’s lymphomas.
Ann Oncol.
1991;
2
S33-S35
- 9
Gianni A M, Bregni M, Siena S. et al .
High-dose chemotherapy and autologous bone marrow transplantation compared with
MACOP-B in aggressive B-cell lymphoma.
N Engl J Med.
1997;
336
1290-1297
- 10
Glass B, Kloess M, Engert A. et al .
Dose escalated CHOP + etoposide and repetitive autologous stem cell transplantation
(Mega-CHOEP) in primary treatment of aggressive lymphoma: Dose intensity count
(Abstract).
Bone Marrow Transpl.
2004;
(Suppl 1)
O103s
- 11
Habermann T M, Weller E, Horning S J.
Rituximab-CHOP vs CHOP with a second randomization to maintenance rituximab
or observation in patients > 60 years with diffuse large B-cell lymphoma (DLBCL)
(abstract).
Blood.
2004;
102
233
- 12
Haioun C, Lepage E, Gisselbrecht C. et al .
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s
lymphoma: final analysis of the prospective LNH87 - 2 protocol - a Groupe d’Etude
des Lymphomes de l’Adulte study.
J Clin Oncol.
2000;
18
3025-3030
- 13
Hans C P, Weisenburger D D, Greiner T C. et al .
Confirmation of the molecular classification of diffuse large B-cell lymphoma
by immunohistochemistry using a tissue microarray.
Blood.
2004;
103
275-282
- 14
Kaiser U, Uebelacker I, Abel U. et al .
Randomized study to evaluate the use of high-dose therapy as part of primary
treatment for „aggressive” lymphoma.
J Clin Oncol.
2002;
20
4413-4419
- 15
Klimo P, Connors J M.
Updated clinical experience with MACOP-B.
Semin Hematol.
1987;
24
26-34
- 16
Kluin-Nelemans H C, Zagonel V, Anastasopoulou A. et al .
Standard chemotherapy with or without high-dose chemotherapy for aggressive
non-Hodgkin’s lymphoma: randomized phase III EORTC study.
J Nat Cancer Inst.
2001;
93
22-30
- 17
McKelvey E M, Gottlieb J A, Wilson H E.
Hydroxydaunomycin (adriamycin) combination chemotherapy in malignant lymphomas.
Cancer.
1976;
38
1484-1493
- 18
Milpied N, Deconinck E, Gaillard F. et al .
Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous
stem-cell support.
N Engl J Med.
2004;
350
1287-1295
- 19
Mounier N, Briere J, Gisselbrecht C. et al .
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy
in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Blood.
2003;
101
4279-4284
- 20
Pfreundschuh M, Trumper L, Kloess M. et al .
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment
of young patients with good-prognosis (normal LDH) aggressive lymphomas: results
of the NHL-B1 trial of the DSHNHL.
Blood.
2004;
104
626-633
- 21
Pfreundschuh M, Trumper L, Kloess M. et al .
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment
of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of
the DSHNHL.
Blood.
2004;
104
634-641
- 22
Pfreundschuh M, Trümper L, Ma D. et al .
Randomized intergroup trial of first line treatment for patients below 60 years
with diffuse large B-cell lymphoma with a CHOP-like regimen with or without
the anti-CD 20 antibody rituximab - early stopping after the first interim analysis
(abstract).
J Clin Oncol.
2004;
23
556
- 23
Philip T, Guglielmi C, Somers R. et al .
Autologous bone marrow transplantation as compared with salvage chemotherapy
in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma [abstract].
New Engl Journ Med.
1995;
333
1540-1545
- 24
Reyes F, Lepage E, Munck J N. et al .
Superiority of the ACVBP regimen over a combined treatment with three cycles
of CHOP followed by involved field radiotherapy in patients with low risk localized
agressive non-Hodgkin’s lymphoma: Results of the LNH93 - 1 study (abstract).
Blood.
2000;
96
532a
- 25
Rosenwald A, Wright G, Chan W C. et al .
The use of molecular profiling to predict survival after chemotherapy for diffuse
large-B-cell lymphoma.
N Engl J Med.
2002;
346
1937-1947
- 26
Santini G, Salvagno L, Leoni P. et al .
VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced
diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by
the non-Hodgkin’s Lymphoma Cooperative Study Group.
J Clin Oncol.
1998;
16
2796-2802
- 27
Shipp M A, Harrington D P. et al .
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive
model for aggressive non-Hodgkin’s lymphoma.
New Engl J Med.
1993;
329
987-994
- 28
Shipp M A, Ross K N, Tamayo P. et al .
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling
and supervised machine learning.
Nat Med.
2002;
8
68-74
- 29
Stansfield A G, Diebold J, Noel H. et al .
Kiel Classification.
Lancet.
1988;
1
292-293
- 30
Verdonck L F, van Putten W L, Hagenbeek A. et al .
Comparison of CHOP chemotherapy with autologous bone marrow transplantation
for slowly responding patients with aggressive non-Hodgkin’s lymphoma.
N Engl J Med.
1995;
332
1045-1051
- 31 WHO .Tumours of Haemotopoietic and Lymphoid Tissue. 1 ed Lyon: IARC Press
2001
Prof. Dr. med. Lorenz Trümper
Abteilung Hämatologie und Onkologie, Klinikum der Georg-August-Universität Göttingen
37099 Göttingen
Phone: 0551/398535
Fax: 0551/398587
Email: lorenz.truemper@med.uni-goettingen.de
